We match your needs with high-profile and experienced life science professionals who can provide strategic guidance, open their network for you, and work with you to accomplish your goals. The NOME mentors include professionals from all over the world with diverse backgrounds such as serial entrepreneurs, investors, clinical experts, and representatives from larger biotech/pharma and medtech companies.
Ole Dahlberg has more than 20 years of international life science management experience and co-founder of 3 startups. He is Former Vice President & General Manager at Thermo Fisher Scientific and currently holding board positions at multiple companies in the life science tools, diagnostics and outsource pharma.
Stefan has close to 30 years of experience in global regulatory affairs and drug development, covering early to late-stage development across multiple therapeutic areas. He has experience as head of drug development, global project leader, is an accomplished global regulatory leader across multiple small and large companies.
Stefan Vlachos was Head of Health Works at AstraZeneca from 2021-2024, and serves on the board of the med-tech start-up Uman Sense in Lund. Previously, has been Head of The Centre for Innovation at the Karolinska University Hospital, and in total has 30+ years’ experience from life science/healthcare, IT/telecom, Media/entertainment, and energy.
Hanne Mette is a seasoned life science leader, currently VP at The Life Science Cluster. With extensive CEO and board experience, she brings strategic insight and experience. Previously CEO of Targovax, siRNAsense, and Diatec Monoclonals, she has also advised Innovation Norway, focusing on investor relations, collaboration, and impactful research translation.
A seasoned executive in the life sciences sector with three decades of experience, specialising in pharmaceuticals, medical devices, and services. Proven track record in both small startups and large pharmaceutical companies. Expertise includes strategic planning and commercialisation, with a strong commitment to driving growth through dynamic and motivated teams.
Johan Verbeeck, DVM, is VP of Business Development, Oncology at Johnson & Johnson, leading transactions, acquisitions, and partnerships, including the $2B Ambrx acquisition. Previously, he led Immunology BD, driving major deals like the $6.5B Momenta acquisition. A J&J veteran since 1996, he has a DVM from the University of Gent and an MSc in Toxicology.
Dave Olson is the US Managing Partner for MedTech Bridge, a Danish organization connecting early-stage Nordic life science firms with the US market. He facilitates strategic partnerships that drive growth and revenue for life science innovators.
Malin has more than 15 years of experience in early and clinical-stage drug development and translational medicine and an academic background in clinical immunology. Malin has held various leadership positions in medium and large pharmaceutical companies such as AstraZeneca, Nycomed/Takeda, and Ferring Pharmaceutical. Malin has in-depth experience in understanding the drug development process from early discovery to commercialisation.
Anders has 30+ years of executive experience in USA and internationally, both in large pharma (Novo, Sanofi, Lilly) and biotech. He has led development, licensing activities, IPO and launched several drugs within Endocrinology and Technology. His focus is Development and Medical Affairs, building strategies that both satisfy Regulators and support successful launch and use.
Anders is an experienced leader in the pharma industry, with an educational background as MD, Ph.D., and eMBA. He has led organizations within Commercial Innovation, including Digital Health, Medical Affairs, Clinical Operations, Regulatory, Quality, and Safety.
From Associate Professor at Karolinska Institutet to 19 years of experience in the pharmaceutical industry, Anders is now chairman and director of the board of several companies.
Anders is a biotech entrepreneur with a background as a VC investor at BankInvest Biomedical Venture. He brought Orphazyme to IPO on Nasdaq Copenhagen in 2017, raising 80M€.
Anders has broad experience in the health care and biotech industry, covering C-level positions, strategy and business development, research collaborations, licensing deals, M&As, and IPOs. He has extensive experience with establishing and developing early-stage biotech companies, as well as fundraising and private placements as an investor.
25+ years of experience in operative strategic marketing and sales operative management in the life science sector.
30 years experience in biotech and pharmaceutical industries. Worked in business development, IPR and innovation management as well as a research scientist.
Entrepreneur and regulatory expert with a passion for phase II-III development and tailormade study design. Background from regulatory affairs and biostatistics.
Arne has 30+ years of experience within the life science industry. He is leading Ankor Consultants Ltd, where he is serving clients in e.g. commercial development, market entry strategies and M&A activities, mainly in the health care and life science industry.
Senior Leader and Medical Doctor with 20+ years of experience in the pharmaceutical industry. Possesses deep experience in drug development, medical affairs, clinical development, clinical operations and commercial strategy.
Carl’s research has resulted in several spin-out companies, and he serves as Chairman of several boards. His main research interests are cancer proteomics for early detection and immuno-oncology.
Catharina has 30+ years of sales and marketing experience in the biopharmaceutical industry across primary care, specialty care, and rare disease products.
Cecilia has 20+ years of experience in life sciences and applied markets, from lab to marketing, from commercialization to sales. Her passion is in business and market development, technology, communication, and user experience.
Commercial Executive with extensive experience translating scientific and commercial ideas into successful market launches for the biotechnology industry.
Chelsea is a gastroenterology/hepatology clinician with 10+ years in startup commercialization and growth. Her expertise is in early innovation and early commercial development, investor relations, stakeholder engagement, business strategy, complex problem solving, KOL strategy, launch readiness, and diversity, equality, inclusion (DEI). She has strong core values and well-maintained, global life science network.
Chia-Feng (CF) Lu spent his career at Celgene, Takeda, and two international law firms to support life science and emerging companies’ expansion to key markets in Europe, the U.S., Asia, and Latin America by navigating the complicated product regulatory and pricing issues worldwide, and representing them in the licensing, financing, partnership, and M&A.
Christian is a professional and experienced science and technology advisor, business leader, and entrepreneur. He has a long track record of starting, developing, and transforming life science and tech companies both in a startup and corporate environment.
Christian has experience from both startup and established companies in engineering, operations, and technology management roles. He has managed clinical testing programs of medical devices in the fields of hearing testing, EEG, and EMG, and is the inventor of several patents.
Christian worked as a veterinary physician/surgeon and assistant professor before moving to pharma and biotech where he has spent the last 20+ years in R&D, Corporate and Executive roles. Christian has co-founded several companies and is the co-inventor on 20+ patents and patent applications.
Christian has been the CEO and member of executive management groups in multiple international high-performance companies, and served as Chairman of the Board and non-exec member of the Board in private equity-owned and public companies.
Christina has 20+ years of experience across Biotech, Medtech and Pharma companies. She specializes in commercializing assets across the globe.
Experienced corporate VP with a comprehensive track record of leading change and delivering impact. Profound understanding of the pharmaceutical value chain through leadership positions across Commercial, Operations, Product development and Compliance functions. Background in management consulting and a Master of Science within Chemistry.
Dr. Richter is an accomplished pharma/biotech executive with a proven track record of success in management and commercial leadership within both the U.S. and international markets at leading companies including Amgen, Takeda Oncology, and LEO Pharma. She has spent most of her career at Amgen, predominantly in Oncology/Hematology with additional work in General Medicine, and Rare Diseases.
Christoffers is a senior executive with a strategic mindset and a proven track record within sales and marketing, with extensive experience in the healthcare industry.
Claus is an experienced biotech executive and holds an MD degree and a PhD in sarcoidosis pathobiology from the University of Copenhagen. His clinical experience is mainly in internal medicine, with clinical development experience in psychiatric and neurodegenerative diseases. He is currently a Venture Partner in The Mission Fund and a part-time CEO of Forward Pharma.
Seasoned serial entrepreneur with extensive experience working with early-stage life science companies as a co-founder, certified and examined board member, chief executive and strategic advisor.
Claus is an experienced executive, board member, investor and advisor. He is leading the Nordic Healthcare Group, a pioneer in social and health services development.
An experienced business and investment advisor, Dag is founder and senior advisor with a focus on start-ups of connected health.
Daniel brings 20+ years of drug discovery and early development experience from biotech and pharma, including operational and strategic management of early R&D organizations.
Dean is a global business executive with 25+ years of experience. He has assisted companies of all sizes to find and execute on new growth opportunities across a broad range of diagnostic and therapeutic applications in numerous disease areas. Named the NOME Mentor of the Year 2021.
With a Ph.D. in Toxicology, Donald has 40+ years of academic and commercial experience within the life science industry. He is the President of White City Consulting, and acts as a chairman and board member of multiple biotech companies.
C-level executive with broad multicultural experience in the health care industry, including Life Sciences, Diagnostics, Medical Devices and Pharmaceuticals in B2B and B2C. Excellent track record in executive management, strategy, business development, marketing and sales.
Duncan is a recognized R&D leader with a strong business-focused vision who successfully lead international product innovation and development teams towards the development of over 75 commercialized pharmaceuticals, agricultural, and specialty chemical products.
Elin has nearly two decades of experience in the pharmaceutical industry in local, regional, and global commercial roles. Her expertise lies in marketing, strategy, commercialization, launch readiness and project leadership, supported by a robust network spanning national and international spheres within the pharma, clinical, and academic communities.
Jon helps life science companies develop strategic go-to-market plans to ensure access, and to reach therapy goals, including Patient Support, Pharmacy network, distribution and technology solutions. Jon has been in the pharmaceutical/Biotech and medical device industry for 40 years and is well versed in patient/provider support programs, market access solutions, specialty pharmacy, and distribution.
Ekaterina is an operator who turned VC. She acts as a board member of multiple companies, and an expert advisor for the European Commission.
Solid international life science experience (diagnostics, MedTech, personalised medicine and IoT solutions) from startup to global commercialisation. Outsourcing/partnerships. Investments and M&A.
Eric has 20 years’ experience as a life science executive and advisor, including academic roles and as VP for early clinical development CV & GI at AstraZeneca and senior medical director for eastern Europe, Greece and Israel for Allergan.
A global business leader and entrepreneur based in Switzerland, Erik most recently was CEO & led Nordic Nanovector ASA. He has worked with some of the world’s top pharma and biotech companies as well as small, highly specialized start-ups. He has spent 25+ years in biotech leading cross functional teams in global sales, marketing & management roles, launching numerous highly innovative products.
Eva has extensive experience in operations and supply chain management, both operational and strategic. Currently, she is a consultant at Inflecto and owner of Better & Beyond AB.
Eva has 25+ years experience from the life science industry within R&D, product development, supply chain management/manufacturing, in-sourcing/out-sourcing, and sustainability. 10 years as CEO of APL and mgmt. positions at AstraZeneca.
Filipe has 15+ years of international experience in the life sciences industry, ranging from local Nordic to European and Global HQ commercial leadership roles, focusing on the development and execution of pricing and patient access strategies for highly innovative therapies in cell & gene, rare diseases and hemato-oncology arenas.
Finn has 20+ year of international experience in Medtech. He was SVP at Coloplast, has been involved in several start-ups, AND taken a company to a listing at NASDAQ.
Giles is experienced in early-stage company formation, seed investment, and business development. He has established multiple companies and partnerships in the drug discovery space, and been involved in major partnering deals with the pharma industry.
Gitte has 20+ years experience from the life science industry with a special focus on commercial development and market access strategies in the Danish, Nordic and European market – with primary areas of operational and strategic management, stakeholder management, market access, product launch, supply and sustainability.
Göran is an experienced leader in the biotechnology industry, with an educational background as MD, Ph.D. in Biochemistry. Spent 16+ years at Active Biotech before joining Cantargia as CEO.
Hanne is an experienced executive within the biotechnology and pharmaceutical industry, having spent 14+ years at Zealand Pharma and 16+ years at Lundbeck.
Hans Peter is a serial entrepreneur, who has experience as a financial analyst and from the pharmaceutical industry. He is now an independent advisor and chairman of BoD of PCI Biotech.
Based on a background as a Medical Doctor and scientist, Hans is an experienced biotech executive with a solid background in corporate strategy, financing, management, drug discovery and development.
Experienced board member, CEO, CFO and private investor with a background in investment banking, investments in life sciences and member of executive management teams in both biotech and other industries.
Co-founder and former CEO of 3Dintegrated (acquired in 2019). One of the few in DK to have led a medtech/deeptech startup to exit to a large strategic at a pre-sales stage. Extensive experience working with commercialization and acquisition of early stage life science technologies through various roles in global companies like J&J, Lundbeck and Buck Institute for Age Research. Has been part of the startup ecosystem for the past 15 years working out of both the US (Silicon valley) and Denmark.
Henrik has a long lasting career in the financial sector. His experience is not limited to fundraising, valuations, capital strategy and M&As.
Hervør has experience with early-stage life science start-ups, company creation and business development. She has a background of 20+ years from biotech business and global pharma with knowledge in therapeutic area strategy, drug discovery, boards and fundraising.
35+ years of experience in specialty care, building organizations and launching products in Nordic/Europe in small and large Pharma/Biotech companies.
Former financial analyst, venture capitalist and head of business development within the life science industry, Hilde is currently COO of NorthSea Therapeutics.
Ilari has 30 years of experience in diagnostics, medical devices and healthcare. He is CEO of Uniogen and acts as board member within the industry.
Inger is a senior executive with a global perspective and strategic mindset, with extensive experience from the Life Sciences/MedTech industry. She has a proven track record within marketing & sales, and as CEO in privately owned middle-sized companies as well as board director.
Jack is a life science VC investor with 20+ experience and deep knowledge in therapeutics, biotech, and medical devices. He acts as a board member of multiple companies.
Jenni is an committed and active expert in the field of oncology drug development from science to business. She acts as the Director of External Science and Partnering, Oncology, Research and Development at Orion Corporation.
Jenny has extensive international experience of driving pharmaceutical development, pre-commercialization and launching products. She has worked in big pharma and as CEO in the biotech world, with experience from medical device and pharmaceuticals in renal, respiratory, oncology and inflammation. Jenny excels in investor relations, communication, and interpersonal relationships.
Jens has a wide background in international MedTech market access and commercial strategy, with an extended emphasis on the US market. His passion lies in the intersection of innovation, commercial design, stakeholder management, and healthcare policy dynamics.
Joachim has more than 20 years of experience in the life science industry and has held positions like VP at AstraZeneca and Chief Medical Officer at Kancera.
Joan is an internationally experienced life sciences executive with a strong connection to the Nordics. She has held leadership roles in high-growth, innovative companies including Novo Nordisk and several early-stage biotechnology companies across Europe and US.
Johan has long operational experience from the Pharma and Biotech Industry as a CEO, in Business Development, R&D projects, and people management. He has been active in venture investing, company creation and board work across Europe and USA.
After 35 years at PwC as auditor and partner with pharma and life science experience, Johan is now associate partner at Sponsor Capital Oy.
Trained in emergency medicine and medical informatics, Dr. Halamka has been developing and implementing health care information strategy and policy for 25+ years. He holds a M.D. from the University of California and a M.S. in Medical Informatics from Harvard University and MIT.
John has 35+ years of international experience in the Medtech Industry. He has experience from bringing innovative products to market. John was the former CEO at Spermosens AB, which he took to listing at Spotlight Stock Market.
Jonas has year-long knowledge and experience with early-stage research-based companies in the immune-oncology sector and acts as a chairman and board member of multiple companies.
Jonathan P. Gertler, MD has more than 35 years of clinical and scientific experience, and extensive advisory work with biotechnology, medical device, diagnostic, and health care IT companies in both the private and public sectors.
Jonny has an educational background as MD and Ph.D. He has worked with innovation for 13+ years at inven2 and Medinnova, and as Head of Biology at GE Healthcare for 17 years.
Jørgen has 30+ years of experience in the pharmaceuticals industry from working at leading companies, including Novo Nordisk and LEO Pharma. He is currently working as an executive coach for corporate clients and board member.
Juuso is an innovative and strategically minded cardiologist (MD, Ph.D.), with extensive experience in medicine and business. CEO and Medical Officer at Precordior, a mobile application-based technology to improve the detection of heart disease.
Jyrki has 30+ years of experience from the pharmaceutical industry and is now Senior Advisor at Modulight and chairman of the BOD of Santen.
18 years of entrepreneurial and investment experience in the healthcare and biotechnology industries, and board member/observer in 10 disruptive health/biotech growth companies.
Kari has more than 20 years of experience from the pharma industry. She is non-executive director of BerGenBio AS and director of the board of Lytix Biopharma AS.
Karin has extensive knowledge of pharmaceutical and clinic development from big pharma as well as broad experience as board director in several life science start-ups.
Kati has a long history in R&D and business roles in the global pharmaceutical industry with a good understanding of current business strategies and models, their potential shortcomings as well as opportunities arising with new technologies.
Kerstin is a business advisor with an extensive network and experience in the life science industry, from CEO to board member and chairman. Her expertise includes strategic marketing, market entry strategies and international business development. She has helped start-ups and established life science companies in biotech, medtech and diagnostics.
Kirsten has more than 25 years of experience in marketing strategy, life cycle management, marketing tactics and communication in IVD and medical device companies.
Kjetil has extensive experience in entrepreneurship and biopharma/Medtech, with a demonstrated history of product development and commercialization both through partnership and own commercialization in major markets.
Koray is an innovation executive specialized in a broad variety of healthcare and personal health applications with a technology background, combined with 15+ years of healthcare/medtech industry experience.
US-based corporate life sciences and healthcare lawyer, entrepreneur and active angel investor with deep experience in the Nordics.
Kush is a serial entrepreneur in medtech, life sciences and cleantech and has been the founder of Spermosens, Diagonal Bio, Prolevi Bio, Avsalt and Thyrolytics. Today he runs his own venture building firm Nested Bio, serves as a board member for listed and private companies, and supports SMEs in the region.
Plentiful pharmaceutical and medical leadership experience across therapeutic areas in global pharma corporations in Europe and USA. Currently developing novel treatments for renal cancer. Lars has also several board assignments at SMEs.
Lars has 30+ years of international experience from pharma/biotech companies focused on global drug development, licensing and commercialization. He has worked with strategy creation and communication at product and therapy area level across different diseases on a regional and global scale. His interest and expertise lies in connecting science with patient needs.
Lars is a senior executive and medical doctor with a passion for fighting cancer and infectious disease by using AI. He is the former VP of Commercial Affairs at Bavarian Nordic and an investor of several companies.
Life science executive with strong international experience and entrepreneurial mindset. Lasse has 30+ years of experience in the pharmaceuticals industry and is an experienced investor and board member.
Liselotte has 25+ years of experience in pharma with deep knowledge and understanding of drug development and medtech. Key experience from first in man trials trough clinical development including global regulatory negotiations and understanding of market access needs and drivers for commercial success. Board and advisor role experience.
Lone is a biotech executive with a love for novel therapeutics and exciting science. She has 20+ years R&D leadership experience from several global pharma and currently focus on biotech business and therapeutic area strategy, financing, drug discovery to clinical PoC, day-to-day project and people management.
Biopharmaceutical industry professional with 25 years of experience in life sciences, in vivo, and people management in a global setting with a broad knowledge of drug discovery processes.
25+ years of biotech and pharma experience. Co-founder of Nuevolution, bringing DNA-Encoded Library (DEL) technology from concept to world leading drug discovery platform. Wide experience in technology innovation, target discovery, data science and research IT. Currently drives integration of machine learning, AI and DEL technologies for small molecule research at Amgen.
Business Development professional and innovation orchestrator with +25 years of pharma expertise. Associate Professor at Sahlgrenska Academy and board member of UN Global Compact.
Marianne works at Innovation Skåne as Director of HealthTech Nordic. Before Innovation Skåne, Marianne worked for 15 years in international business development at Tetra Pak and Alfa Laval, as well as nine years as entrepreneur and management consultant in various industries.
Maris has 30+ years of CEO and senior executive R&D management experience from the international life science industry. He is a trusted advisor and board member of numerous companies.
Marjo is an experienced business leader and mentor, currently leading ResQ Club in Finland. Her key competencies include HR and change management, planning and forecasting, and line management and leadership.
Marko is a seasoned commercial leader, executive and a venture capital investor with experience in digital health, international health tech, health care and med tech sectors. He has held commercial leadership roles in multiple companies, e.g. Mobidiag (acquired by Hologic in May 2021) and, recently as CCO of Kaiku Health (acquired by Elekta in May 2020). He is also a mentor in the SPARK Finland program, and has served as an advisor to several digital health companies.
Martin has more than 20 years of international experience and currently lives in the USA. During that time, he has been the BU leader in companies such as Bristol Myers Squibb (now ConvaTec), Becton Dickinson (BD) & ICU Medical. Martin is originally from Denmark and holds a M.Sc. (Econ.) from Copenhagen Business School (CBS).
Martin is co-founder of MedTrace Pharma A/S and led the company to its phase III trial initiation in 2022 as CEO. Martin has been in life science throughout his career and posted twice (USA and Germany). Focus is commercial and business development within device, diagnostics and pharma.
Masha has experience from investment banking with focus on biotech and medtech. She is a now an investor and advisor and VP of corporate development at Fortuna Fix.
Leads the Clinical Operations focusing on the planning and execution of clinical trials in the Rare Endocrine, Rare Blood disorders, and Stem Cells areas at Novo Nordisk.
Mona is a seasoned Med Tech professional with more than three decades of experience. She has held a number of positions at Norwegian, Nordic and European levels with extensive experience from sales, market, business development, HR processes and team building, networking, KOL strategies, management, leadership and execution. Mona currently serves as a board member in two start ups within Med Tech and runs her own consultancy business in parallel.
Monica Alfaro Welling is a seasoned biopharma executive with over 30 years of experience working in a variety of strategic and operational executive positions in multi-national biopharma companies, start-ups and boutique consulting firms.
Morten is an experienced executive and a seasoned entrepreneur with a strong medical, commercial and financial background within life science.
Morten has 20 years of international experience with BD in big-pharma, specialty-pharma and biotech (AstraZeneca, Nycomed, Grünenthal and Medivir).
Neil is a serial entrepreneur with vast experience from the life science sector. He is co-founder of Double and helps build life science companies.
A board- and C-level experienced biotechnology executive with wide-ranging knowledge and skills in company formation, fundraising, intellectual property, licensing, business development and the underlying science of the industry.
Niels Erik is a co-founder of Innoventa Medica, Reapplix, Vivostat and other medical device companies. He has invented several medical devices that have been CE marked and FDA approved, and has been responsible for several clinical trials. He has more than 25 years of experience in the Medtech field.
Nikolai has extensive experience and expertise in drug development of biologics in inflammatory disease as well as oncology and hematology. He has worked as Medical Officer, as a regulator and in executive positions in a number of international biotech and pharmaceutical companies, as well as passing on his expertise as professor of Regulatory Science.
Ole has a background in VC and is currently supporting Coloplast’s business areas of Ostomy Care, Continence Care, Wound Care, and Surgical Urology from their Partnership function. He has acted as a board member of multiple companies.
Øyvind worked 7+ years as the CEO for the biotech company Ultimovacs, and is today Chairman of the Board for numerous life science companies.
Patrick is a business development executive in healthcare. Patrick’s interests and knowledge are in data-driven healthcare management and solutions that enable primary prevention through digital channels.
Patrik Strömberg has more than 20 years of experience from the pharmaceutical industry, and has worked in leading roles in both R&D, innovation management and business development. He has a PhD in Biochemistry from Karolinska Institutet and an MBA from Stockholm University (Stockholm Business School), and also serves as an independent director of the boards at Strike Pharma AB and AAX Biotech AB.
Paul has 30 years’ experience from international company leadership, commercial operations and business- & corporate development in public and PE/VC-owned companies as well as in entrepreneurial start-ups. He has extensive hands-on experience in licensing and M&A dealmaking, go-to-market strategy and commercialization in the US and Europe, IPOs and fund raising for Pharma, Biotech and Medtech companies.
Pekka Kahri is the Technology Officer at Helsinki University Hospital (HUS), the biggest public healthcare provider and academic medical centre in Finland. He is passionate about digital health innovations and collaboration between public healthcare providers, companies and academia.
Per has 20+ years of experience in the pharmaceuticals and biotech industry. For the last 10 years, he has worked as CEO and CMO for Alligator Bioscience, Xintela, Targinta and Evaxion.
Peter Bak, PhD has more than twelve years of experience with a broad range of research approaches—cellular, molecular and biochemical—and fields—from immunology and infection through oncology.
Peter is the Founding Partner of Sunstone, one of the leading Venture Capital funds in Scandinavia. He serves as Chairman of several boards, and his specialties include strategy, venture capital, and business development.
Peter is a board member of multiple biotech and life science companies. He previously held academic roles and senior management positions at leading companies such as AstraZeneca, Orexo and Swedish Orphan Biovitrum.
Peter has been part of the biotech and pharma environment for 20+ years and is a co-founder of multiple companies. As a researcher, a patent attorney, an executive manager, a strategic business developer, and a founder, he bridges science, business, IP, academia, and industry.
Experienced advisor and C-level executive with 25+ years of experience within innovation, technology and research at e.g. Chr.Hansen and CP Kelco.
Rasmus, M.Sc., is co-inventor of the 3C Patch® technology and co-founder of Reapplix A/S. As CSO Rasmus participated in taking the company through early pre-clinical and clinical development to regulatory clearances in EU and US. Focus is from science to product development, early market access and market entry within device and biotech.
Roger is a board certified oncologists with a doctorate in experimental oncology from the Karolinska Institute. Senior management positions in Scandinavian biotech companies in early and late development as well as leading medical roles and advisor to global biopharma companies. He is currently Chief Medical Officer at Isofol, and also board director and member of scientific advisory boards to startup companies.
Rolf has more than 30 years of experience in life science and diagnostics companies. He is now partner at Ventac Partners.
Through his 15+ years expertise across Oncology R&D and commercial roles, Sav has become an industry leader in oncology product and portfolio strategy. Sav is adept at engaging investment boards, senior management and stakeholders to drive decision-making and impactful investments that can make a difference to patients around the world.
Shori is a health care entrepreneur with expertise within strategy and investment within Med tech and welfare technologies. She formerly built Avesina Health Care, a private care provider in Sweden. The company was operating within primary and specialist care along with diagnostics and elderly care.
Simon is currently Chief Scientific Officer and board member at Draupnir Bio, Associate Professor in Neurobiology at Aarhus University, and member of the Innovation Committee at the Novo Nordisk Foundation. He has +20 years of experience in life science R&D and entrepreneurship, and is co-founder of the three biotechs Draupnir Bio, Muna Therapeutics, and Teitur Trophics, raising more than 130 M EUR in venture capital.
Highly accomplished pharma/biotech executive with a proven track record in commercialising innovative therapies, including ATMPs and gene therapies. Recently served as SVP Global Commercial Head at GenSight Biologics in Paris, and VP and GM for Mid-Sized Countries in Europe at Novartis Gene Therapies. Possesses a strong foundation in partnerships, business development and M&A.
Søren is a serial entrepreneur with an outstanding pharmaceutical and healthcare industry international experience.
Søren Bregenholt holds a PhD in biomedical research and has more than 20 years of international experience from operational and strategic leadership positions in global pharma and the biotech industry including executive roles at Novo Nordisk, Symphogen and Alligator Bioscience. During he careers, he has negotiated and operationalized numerous licensing, collaboration and co-development agreements.
Stefan is an experienced medtech and clinical diagnostic leader with a career focus in clinical and corporate development, sales and marketing. He has previously been the CEO at Clinsight, and has more than 15 years of experience in bringing innovative technologies and products within medtech and diagnostics to market in Europe and the US.
Sumeet is a Physician-scientist (MD) with ~20 years experience covering clinical care, academic and pharmaceutical research and development & executive medical leadership in global Oncology-Hematology & Immunology drug development, global regulatory submissions & approvals. Sumeet is currently the Chief Medical Officer at Alligator Bioscience AB, an emerging clinical stage biotech company developing a pipeline of novel mono- and bispecific immuno-oncology antibodies.
Sveinung has 20 years of experience from Life Science business development, has negotiated trade sales and been lead investor/board member in IPOs. He is Managing Partner of the early-phase VC fund Sarsia.
US-based serial entrepreneur and board member with experience in acute care, neurology, cardiovascular, orthopedic, and vascular access fields.
Sylvie is a senior advisor and consultant with extensive network and experience in life science and innovation. She has held several global positions in strategic marketing and business development and she has also worked on the interface between academia, public-private partnerships, and industry collaborations.
Thomas has 20+ years of working with people and issues in many contexts – from basic research to green innovation, management, and customer collaborations in the business world.
Thomas has more than 25 years in the white biotech space. Currently he leads the BioInnovation Institute Initiative as a project director.
Entrepreneur, investor, board member, and Managing Director at Digital Research Centre Denmark (DIREC), a Danish national centre for research, innovation and education in digital technologies.
With +20 years in pharmaceutical R&D, Thorsten is a seasoned leader who knows how to build and lead strong performing teams to advance drug discovery and early development projects. His leadership experience spans leading teams in Copenhagen, Boston, and San Francisco as well as driving R&D partnerships across Europe, Asia, and North America.
Tomas has 20+ years of experience in international marketing and sales, primarily within medical technology and diagnostics, including 10 years+ of experience as CEO at multiple life science companies.
Torben was medical and hospital director at the hospitals Amager and Hvidovre. He has more then 30 year experience in the healthcare sector.
Torben has 20+ years of experience in the pharmaceutical and biotech industry, as a CEO, COO, and advisor. He has also spent 10+ years providing corporate finance advice to therapeutics, diagnostics, and medical device companies.
Tord is an associate professor of immunology and has accumulated more than 15 years of extensive international experience in the pharmaceutical industry, within Research and Development, Medical Affairs, and as a CEO/General Manager. Tord’s tenure inTokyo with LEO Pharma has equipped him with a substantial network in Asia.
Trond has 20+ years of experience in building and managing companies, and his key competencies include medical devices, product launches, and business strategies.
Ulla is a serial entrepreneur, Founder/Co-founder of 3 companies with 25 years of experience in biotech. She has solid experience from listing 3 companies on the Danish and Swedish stock markets and was a key player in 2 product approvals by FDA and EMA.
Ulrik is an active business angel and director and has 20+ years’experience from life science investmenting. He was lastly Managing partner of Large Investments at Novo Holdings.
Will has been involved in the start-up scene for more than 20 years,as an investor, entrepreneur, and everything in between. His interest lies in areas related to digital health, education, and environment – anything that can have a dramatic impact on human wellbeing.
Wing is a Life Science Executive with an extensive network and experience in the life science industry, from CEO to board member and health authority expert. He has worked with health economics, regulatory affairs, portfolio management, business development, pricing and market access. Wing has broad experience from health authorities and life science companies in the diagnostics and pharmaceutical fields.
Yvonne has extensive international experience in marketing and sales. She is a board member and chairman for several life science companies.
Malin has more than 15 years of experience in early and clinical-stage drug development and translational medicine and an academic background in clinical immunology. Malin has held various leadership positions in medium and large pharmaceutical companies such as AstraZeneca, Nycomed/Takeda, and Ferring Pharmaceutical. Malin has in-depth experience in understanding the drug development process from early discovery to commercialisation.
Frances Stocks Allen is an experienced lawyer for innovative, high growth life sciences companies and their investors. She is a partner at US law firm Cooley LLP and is based in London. She specializes in cross-border licensing, collaboration, co-development and other strategic transactions. She helps company leadership to develop transactions which deliver against their goals.
A serial entrepreneur, Auvo has over 25 years of medical device experience from start-ups as well as from listed companies.